Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What You Need to Know Ahead of Abbott Laboratories' Earnings Release

Valued at a market cap of $217 billion, Abbott Laboratories (ABT) is a healthcare company that develops, manufactures, and sells a broad range of medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. The North Chicago, Illinois-based company is expected to announce its fiscal Q4 earnings for 2025 in the near future.  

Ahead of this event, analysts expect this healthcare company to report a profit of $1.50 per share, up 11.9% from $1.34 per share in the year-ago quarter. The company has met or surpassed Wall Street’s bottom-line estimates in each of the last four quarters. In Q3, ABT’s EPS of $1.30...

Fundamentals

See More
  • Market Capitalization, $K 217,080,768
  • Shares Outstanding, K 1,738,872
  • Annual Sales, $ 41,950 M
  • Annual Income, $ 13,402 M
  • EBIT $ 9,438 M
  • EBITDA $ 12,656 M
  • 60-Month Beta 0.72
  • Price/Sales 5.17
  • Price/Cash Flow 18.96
  • Price/Book 4.23

Options Overview Details

View History
  • Implied Volatility 22.43% (+1.19%)
  • Historical Volatility 20.12%
  • IV Percentile 56%
  • IV Rank 22.89%
  • IV High 42.50% on 04/07/25
  • IV Low 16.47% on 01/24/25
  • Expected Move (DTE 5) 1.87 (1.50%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 3,900
  • Volume Avg (30-Day) 7,094
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 194,644
  • Open Int (30-Day) 195,706
  • Expected Range 122.97 to 126.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.50
  • Number of Estimates 9
  • High Estimate 1.51
  • Low Estimate 1.49
  • Prior Year 1.34
  • Growth Rate Est. (year over year) +11.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.70 +3.43%
on 12/10/25
129.85 -3.86%
on 12/01/25
-3.70 (-2.88%)
since 11/26/25
3-Month
120.70 +3.43%
on 12/10/25
135.45 -7.83%
on 10/01/25
-8.71 (-6.52%)
since 09/26/25
52-Week
110.86 +12.61%
on 01/15/25
141.23 -11.61%
on 03/04/25
+9.57 (+8.30%)
since 12/26/24

Most Recent Stories

More News
What You Need to Know Ahead of Abbott Laboratories' Earnings Release

Abbott Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a low double-digit profit growth.

ABT : 124.84 (+0.02%)
XLV : 156.05 (+0.16%)
$SPX : 6,929.94 (-0.03%)
This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?

Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?

ABT : 124.84 (+0.02%)
Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength

Broadcom, Abbott, and Nordic American raised dividends, offering strong yields and long-term upside despite market volatility and sector headwinds.

NAT : 3.43 (+1.18%)
MSFT : 487.71 (-0.06%)
ABT : 124.84 (+0.02%)
AVGO : 352.13 (+0.55%)
Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

ABBOTT PARK, Ill. , Dec. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt™ PFA System to treat patients battling...

ABT : 124.84 (+0.02%)
Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

ABBOTT PARK, Ill. , Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery...

ABT : 124.84 (+0.02%)
1 Safe-and-Steady Stock to Consider Right Now and 2 We Turn Down

1 Safe-and-Steady Stock to Consider Right Now and 2 We Turn Down

ABT : 124.84 (+0.02%)
EPC : 17.48 (+0.23%)
FAF : 61.93 (+0.98%)
Abbott increases quarterly dividend for 54th consecutive year

ABBOTT PARK, Ill. , Dec. 12, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase...

ABT : 124.84 (+0.02%)
AI Turns Health and Wellness Data into Gold as $110B Market Explodes by 2030

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence is turning fragmented health data into actionable insights, fundamentally reshaping how patients,...

ABT : 124.84 (+0.02%)
WELL.TO : 3.97 (unch)
MDT : 96.52 (-0.04%)
WHTCF : 3.1440 (+9.55%)
RDNT : 73.15 (+0.29%)
ALEN-U.CN : 1.4500 (unch)
Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data

ABBOTT PARK, Ill. , Dec. 8, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that Lingo , an over-the-counter continuous glucose monitor (CGM) and app, is now available for Android devices....

ABT : 124.84 (+0.02%)
2 Mega-Cap Stocks with Promising Prospects and 1 Facing Challenges

2 Mega-Cap Stocks with Promising Prospects and 1 Facing Challenges

ABT : 124.84 (+0.02%)
MA : 579.60 (+0.03%)
PEP : 143.78 (+0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures...

See More

Key Turning Points

3rd Resistance Point 126.19
2nd Resistance Point 125.69
1st Resistance Point 125.26
Last Price 124.84
1st Support Level 124.34
2nd Support Level 123.84
3rd Support Level 123.41

See More

52-Week High 141.23
Fibonacci 61.8% 129.63
Fibonacci 50% 126.04
Last Price 124.84
Fibonacci 38.2% 122.46
52-Week Low 110.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar